Relmada Therapeutics Company Insiders

Relmada Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.8824) % which means that it has lost $0.8824 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6026) %, meaning that it created substantial loss on money invested by shareholders. Relmada Therapeutics' management efficiency ratios could be used to measure how well Relmada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 22, 2025, Return On Tangible Assets is expected to decline to -1.83. The current year's Return On Capital Employed is expected to grow to -2.24. At present, Relmada Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 169.6 M, whereas Non Current Assets Total are forecasted to decline to about 20.9 K. The current year's Common Stock Shares Outstanding is expected to grow to about 31.7 M, whereas Net Loss is forecasted to decline to (148.4 M).

Relmada Therapeutics Workforce Comparison

Relmada Therapeutics Insider Trading

Relmada Therapeutics Notable Stakeholders

The success or failure of an entity such as Relmada Therapeutics often depends on how effective the management is. Relmada Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Relmada management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Relmada management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Relmada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Relmada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Relmada Therapeutics' management manipulating its earnings.

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.